Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Non-Small Cell Lung Cancer EGFR Mutated (Mar 2021)

Posted by Matt Breese on Mar 12, 2021

Find me on:

According to our recent payer coverage analysis for non-small cell lung cancer EGFR mutated treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer EGFR mutated treatments shows that under the pharmacy benefit, about 60% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-NSCLC EGFR-1Q2021Data snapshot as of Q1 2021

Trends: Many drugs to treat NSCLC are on the market today, and multiple ones are in Phase III trials. The discovery of genetic alterations that drive tumor growth has changed the clinical management of the disease and produced specific targeted therapies to treat the various genetic mutations.  

To read the full Reality Check on Non-Small Cell Lung Cancer EGFR Mutated treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing